The chronergy of recombinant streptokinase thrombolysis in acute myocardial infarction

نویسندگان

  • ZHONG-MING WANG
  • YA-BING LIU
  • QI-CHEN JIN
  • XUE-QI WANG
  • MENG DAI
  • HUI SHAO
  • WEN-PING ZHAO
  • QIU-LI DONG
  • SHU-PING WANG
  • HAI-TAO ZHANG
  • LI-CHA KONG
  • SHAO-YUN LIU
  • DONG-YING WANG
چکیده

The aim of this study was to explore the chronergy of intravenous recombinant streptokinase (r-SK) in patients with acute myocardial infarction (AMI). A total of 114 patients were divided into two groups according to the time of AMI onset: the morning onset (6:01-12:00, n=53) and non-morning onset (12:01-06:00, n=61) groups. The recanalization rate was recorded, as well as anticoagulant and fibrinolytic indices. Statistical analysis was performed to evaluate the recanalization rate following thrombolysis, as well as the anticoagulant and fibrinolytic activities. The recanalization rates following thrombolysis in the morning onset and non-morning onset groups were 60.4 and 82.0%, respectively (P<0.05). The level of plasminogen activator inhibitor-1 (PAI-1) antigen was significantly higher in the morning onset group compared with that in the non-morning onset group (P<0.05). This indicated a resistance to r-SK thrombolysis in the morning at the early stage of AMI, which possibly correlates with increased PAI-1 antigen levels and activity.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The streptokinase therapy complications and its associated risk factors in patients with acute ST elevation myocardial infarction

Acute myocardial infarction (AMI) is one of the main leading causes of mortality and morbidity. Despite the progress in the treatment of AMI, streptokinase is still being used in many countries. Because of the critical condition of patients with AMI and complications of streptokinase therapy, this study was performed to evaluate the pattern of adverse drug reaction (ADRs) induced by streptokina...

متن کامل

Anti-streptokinase Antibody Detection before and Immediately after Streptokinase Therapy in Patients with Myocardial Infarction

Background: Myocardial infarction (MI) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries including Iran. Our previous study showed that, the prevalence of high antibody titers a...

متن کامل

The streptokinase therapy complications and its associated risk factors in patients with acute ST elevation myocardial infarction

Acute myocardial infarction (AMI) is one of the main leading causes of mortality and morbidity. Despite the progress in the treatment of AMI, streptokinase is still being used in many countries. Because of the critical condition of patients with AMI and complications of streptokinase therapy, this study was performed to evaluate the pattern of adverse drug reaction (ADRs) induced by streptokina...

متن کامل

Assessing Time between Arriving to Hospital and Administration of Streptokinase in Patients with Acute Myocardial Infarction in Emergency Department of Kerman University of Medical Sciences in 2003-4

Introduction: Acute myocardial infarction is one of the major causes of mortality in developing countries such as Iran. One of the most important progresses in acute myocardial infarction is early administration of therombolytic agents such as streptokinase. This study was performed to determine the time interval from patients’ referral to the emergency wards to the introduction of thrombolytic...

متن کامل

Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?

T HROMBOTIC COMPLICATIONS of cardiovascular disease are a main cause of death and disability and, consequently, thrombolysis could favorably influence the outcome of such life-threatening diseases as myocardial infarction, cerebrovascular thrombosis, and venous thromboembolism. Thrombolytic agents are plasminogen activators that convert plasminogen, the inactive proenzyme of the fibrinolytic sy...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 5  شماره 

صفحات  -

تاریخ انتشار 2013